Cure8 research brief
If you or your clinician are using upadacitinib for Crohn’s, intestinal ultrasound early in treatment may help predict who will not respond and who is more likely to relapse on maintenance dosing, potentially guiding closer follow‑up or earlier treatment adjustments.
Adults with Crohn’s disease starting or on upadacitinib, gastroenterologists and IBD clinicians, and researchers studying IUS as a monitoring tool.
This prospective multicenter cohort study followed 122 adults with active Crohn’s disease treated with upadacitinib (UPA) through 52 weeks and used intestinal ultrasound (IUS) alongside clinical, biochemical, and endoscopic data.
Higher baseline IUS activity (IBUS‑SAS) and failure to reach IUS response/remission after induction were strong predictors of primary non‑response to UPA and of relapse during 15 mg maintenance in this cohort.
IUS added predictive value beyond clinical and endoscopic measures: patients who were clinical or endoscopic responders but did not achieve IUS response/remission had higher relapse risk on maintenance. The study reports odds ratios and survival analyses supporting these associations but is presented here as a summary of the abstract.
Practical takeaway Early IUS monitoring during induction in patients starting upadacitinib may help identify those at higher risk of not responding or of relapsing on maintenance; the findings support considering IUS as part of multi‑modal monitoring rather than as a standalone decision point.
This brief is grounded in the article abstract provided by the journal; Cure8 did not review the full manuscript beyond the extracted text.
This summary is based on the article abstract (structured content depth: abstract). It summarizes associations reported in the study cohort; it does not imply causation or provide treatment recommendations. Further details (methods, full statistics, and applicability to different patient subgroups) would require reading the full paper.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
